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The role of the Epstein-Barr virus in the development of post-
transplant lymphomas is well established. However, not all 
lymphomas that arise in these patients contain Epstein-Barr 
virus, suggesting that other cofactors are involved in tumor 
pathogenesis. We propose that immunologic interactions that 
result from the introduction of immunocompetent donor cells 
during transplantation contribute to a Iymphomagenic environ-
ment in the host. Murine models of lymphoma that arises 
following transfer of allogeneic hematopoietic cells are 
discussed and are related to the transplant setting. One 
contemporary viewpoint of transplantation immunology holds 
that interactions between the host and donor components of 
the immune system determine the ultimate degree of tolerance 
or reciprocal immunoreactivity (eg, rejection, graft-versus-host 
disease) within the transplant patient. We conclude that 
host-donor immunologic microchimerism may also be an over-
looked factor in the development of posttransplant lymphomas. 
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At first glance. the title of this paper appears to be an 
effort to link two entirely unrelated topics. After all, a 
preponderance of studies have established the Epstein-
Barr virus (EBV) as the primal driving force within post-
transplant Iymphoproliferative disorders (PTLD) [11. and 
a depressed host antiviral immune response apparently 
completes the list of factors necessary for production of 
these tumors. Indeed. direct reestablishment of immuno-
logic control [21. most specifically by means such as adop-
tive transfer of anti-EBV-specific. HLA-matched cyto-
toxic T cells [3-5], has been associated with tumor 
regression. Further. some patients who are treated by 
withdrawal of immunosuppression may also reject their 
grafts and thus by definition have not achieved donor-
specific tolerance. What. then. is the impetus that leads us 
to suggest an intersection between tolerance and post-
transplant lymphomas? 
On reflection. several features of PTLD are not easily 
explained by a disease model restricted to understanding 
the interactions between EBV-induced B-celllymphopro-
liferation and defective host immunologic controls. For 
example. not all PTLDs contain EBV. nor are they neces-
sarily even of B-cell origin [6.7-]. 
Conversely. other EBV-associated tumors. such as 
nasopharyngeal carcinoma. do not occur in transplant 
patients with the same frequency as does PTLD. We also 
do not know why a large number of PTLDs are extran-
odal, and a virocentric perspective does not fully explain 
why a disproportionate number of PTLDs occur in the 
allograft [8]. The occasional donor cell-derived PTLD in 
the organ recipient [9] may be a probabilistic phenome-
non, but it might also renect other. poorly understood 
processes. For all of these reasons. it may be worthwhile 
to first acknowledge the importance of EBV and the asso-
ciated host anti-EBV immune response in the pathogene-
sis of these tumors. and then ask where we might seek 
other, cryptic, cofactors that could explain additional 
aspects of posmansplant lymphoid neoplasia. 
Analvsis of risk factors for PTLD has generally sou/?:ht [0 
provide support for. and enhancc our understanding of. 
the EBV hypothcsis_ Thus. primarY \'crsus reactivation 
EBV infection and high Icvels of immunosuppression 
have been shown to predispose to Ivmphoma develop-
ment [10-141. CytomcgalO\'irus infection has also bcen 
considered J risk factor for PTLD. Jmibuted at least in 
part to its association with EB\, reactivation [151. Rcporrs 
of other risk LlCwrs for PTLD are sparse. In an earl\' 
study. BirkcLtnd [11>[ proposed In association bct\\'ccn 
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the degree of HLA mismatch and (lymphoid and nonlym-
phoid) posttransplant tumors. This theory hearkens to the 
concept of "allograft antigenic stimulation." which has 
served as a frequently invoked, but to date unproven, leit-
motif in the discussion of risk factors for PTLD. In 
contrast, a recent report identified good HLA-DR match-
ing as a potential risk factor for this disease [11]. A later 
studv from the same center did not confirm this but did 
show a predominance of HLA-A2, -Bw57, or -DR7 in 
donors for patients who developed PTLD [17-]. This 
finding was interpreted in the context of EBV immune 
reactivity. 
Specific underlying diseases have occasionally been put 
forth as risk factors for PTLD development. Most such 
claims derive from early reports. However, one recent 
study [13] showed a statistically significant correlation 
between Langerhans cell histiocytosis and later PTLD. 
\[ost accepted or speculative factors associated with 
development of PTLD contain elements of either 
immunostimulation or immunologic hyporesponsiveness. 
One phenomenon that incorporates both of these features 
is acquired immunologic tolerance. We can define toler-
ance broadly as " .. a physiologic state in which the 
immune system does not react destructively against the 
organism that harbors it" [18]. 
In order to develop our premise. namely that there is a 
point of intersection between tolerance and PTLD, we 
first present a view of tolerance as one potential end state 
of donor-host immunologic interactions [19"]. Animal 
models of tolerance induction are described and neoplas-
tic complications of these models are shown. The poten-
tial signiticance of these findings to the clinical situation 
is then discussed. 
Transplantation rejection and tolerance 
,\cute rejection is mediated primarily by direct recogni-
tion pathways. in which host leukocytes. predominantly T 
lymphocytes. recognize alloantigens displayed on profes-
~ionalI donor-derived antigen-presenting cells (APCs) 
[18). Such APCs are largely synonymous with the 
"passenger leukocvte" popUlation. Indirect recognition. 
in which host lymphocytes recognize alloantigens 
presented by host-derived APCs. also contributes to rejec-
rion [20-.21], and such T cells can be seen in blood and in 
rhe allograft during rejection episodes. Analysis of indirect 
presentation has shown that one dominant target emerges 
during rhe initial response [221. In subsequent responses. 
additional determinants Olav also be targeted. Thus rejec-
rion is not onh' dynamic but also shows cumulati\'c 
immunologic "learmng." 
The importance of ,\PCs in initi;l[ing rejection was first 
,>uggested 1)\' experiments showing that donor-spet.:ific 
tolerann: could be produced b,' transplantatIOn of an F 1 
I \{xS) EF[~;111 IIHO an \ \{) reClplcnr. follO\\'eu hy rcmll\'al of 
the organ and retransplantation into a second (R) recipi-
ent [23]. This effect was attributed to emigration of 
passenger leukocytes oue of the graft during the primary 
transplant. The tolerant state could be broken with an 
infusion of (RxS) dendritic cell-enriched preparations but 
not by (RxS) B- or T-cell-enriched preparations. This 
implied that the original donor dendritic cell population 
was responsible for the initiation of organ rejection. In 
this view, the organ parenchyma is a silent partner that is 
subject to injury by a rejection reaction first directed 
against or initiated by the donor dendritic cells. 
If this model is a sine quo non of tolerance, then tolerant 
individuals should be devoid of donor dendritic cells. 
This clearly is not the case, as evidenced by persistence 
of these cells in microchimeric patients [24,25]. We 
therefore must concede that survival of donor dendritic 
t.:ells is compatible with tolerance and conclude that 
tolerance represents one steady-state condition of 
microchimerism. This is not the only possible steady 
state, and in other cases microchimerism may exist in a 
host who is devoid of self-sustained donor-specific toler-
ance [26,27]. Persistence of a clinically stable state in this 
circumstance is dependent on continued immunosup-
pression. In the absence of this outside aid, the 
host-donor relationship may proceed to a dysequilibrated 
state reflected by either allograft rejection or graft-
versus-host disease (GVHD). In this viewpoint, the post-
transplant state is viewed as a series of negotiations 
between two immune systems. If successful, coexistence 
is maintained and tolerance achieved. If negotiations are 
unsuccessful, conflict breaks out and the more powerful 
immune system prevails. pillaging the organs defended 
by the vanquished adversary. 
The individual mechanisms that may contribute to 
acquired tolerance induction are reviewed elsewhere [28]. 
These include, eg, veto cells. anergy, clonal deletion, 
suppressor activity, and costimulatory deficient dendritic 
cells [29]. Regardless of the specific pathways, tolerogen-
esis is necessarily an active process in light of the contin-
ued generation of new immune cells by the host (esti-
mated at 2 x 10" T cells and 2 x 107 B cells daily [30]). 
There is also evidence that hematopoietic stem cells from 
the allograft may establish residence in the host and 
generate progeny cells [31]. The relevant question then 
becomes: How do the donor and host immune systems 
achieve a mutual tolerance in some patients but not in 
others. and what complications can arise from this state of 
affairs? 
Murine models of tolerance 
Inoculation of major histocompatibility compiex-<.iisparatc 
hematopoietic l:eIls into neonatal mice leads to donor-
\pecitic immunologic hvporesponsiveness and to toleranl:e 
for grafts from thc donor [321. Such tolerance was origl-
J1;tlly considered a 11l1lque property of rhc n;tscenr immune 
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system with minimal relevance to either the adult animal 
or to areas such as clinical transplantation. t\Iatzinger [30] 
questioned this assumption in the context of her "danger 
hypothesis" for explaining the raison d'ftre of the immune 
system. In her interpretation, the primary purpose of the 
immune system is not to distinguish self from non-self but 
rather to distinguish dangerous from nondangerous envi-
ronments. The hypothesis draws from the two-signal 
theory of Cohn [33], which states that inexperienced 
lymphocytes require two signals for activation and that, in 
the presence of the first signal without the second, they 
will either become tolerant or die. Matzinger suggested 
that the small number of normal, inexperienced T cells 
that comprised the newly developed immune system was 
easily saturated with donor B cells in the neonatal toler-
ance experiments. The B cells supplied signal 1 only, thus 
tolerizing the animal to the donor antigen. As the number 
of recipient immune cells increased with age, an identical 
inoculum would no longer be saturating and some recipi-
ent T cells could receive both signals by interaction with 
the less common donor dendritic cells. This would result 
in sensitization instead of tolerance. The model predicted 
that proper manipulation of donor cell number and compo-
sition could induce tolerance in the adult animal (or sensi-
tization in the neonates). This prediction was verified by 
Ridge et 01. [34-], thereby demonstrating that neonatal 
tolerance follows the same rules as does acquired tolerance 
in the adult and that the neonatal tolerant state is contin-
gent on the interaction between two immune systems. 
Thus, tolerance-generating models of hematopoietic cell 
transfer in neonatal and adult rodents may serve as guides 
to host-donor immune interactions that occur in the 
microchimeric posttransplant setting. Likewise, break-
down of tolerance and complications of host-donor 
immune interactions in the murine model may provide 
signposts to alternative pathways available to the hybrid 
immune system in the transplant patient. 
Lymphomas following transfer of allogeneic 
hematopoietic cells In mice 
Janossy et 01. [35-37] reported an increased frequency of 
lymphomas in mice following induction of neonatal toler-
ance. Tumors were of recipient origin, and analysis of two 
separate lymphomas revealed a T-cell origin in both [36]. 
One tumor induced donor-specific tolerance when 
implanted into syngeneic animals. suggesting that it arose 
from a subset of cells involved in mediating donor-
specitic tolerance in the progenitor animal. 
An increase in the absolute number of cells comprising 
[he donor inoculum was associated with an increase in the 
frequency of recipient Ivmphomas in this model. Infusion 
of disrupted donor cells did nor lead to Ivmphoma devel· 
opment. excluding transfer of virus as rhe cause of 
rumors. Inhibition of donor cell proliferation prevented 
rhe onset of Ivmphomas. and from this tinding the authors 
inferred that long-rerm chimensm was a necessary prereq-
uisite to tumor development. Removal of Thy1 + T cells 
from the donor inoculum moderately reduced but did not 
eliminate tumor development. In these animals. donor-
specific allografts were maintained for variable periods, 
dependent on the particular strain combination. The 
frequency of lymphomas was also related to the individual 
strain combinations used, but this did not parallel the 
degree of tolerance induction and the authors concluded 
that these were independent events [38]. Autoantibody 
formation was observed in a number of animals, and this 
was considered to reflect a component of GVHD activity. 
However, clinical GVHD was not seen. 
These studies expanded the earlier studies of Schwartz 
and Beldotti [39], Schwartz and Andre-Schwartz [40], 
Datta and Schwartz [41], and Andre-Schwartz et 01. [42], 
who showed lymphoma development following murine 
splenocyte transfer. In their model of parental EAF~ 
F1(AxB) cell inoculation, GVHD was a frequent cause of 
early mortality. This could be alleviated by using older 
mice and by treating recipients with a short course of 
immunosuppression. However, mice that survived clinical 
GVHD without immunosuppression also developed 
lymphomas, indicating that drug therapy was not neces-
sary for tumor development. Tumors in this model were 
also of recipient origin [42]. The authors suggested that 
low-grade chronic GVHD, possibly interacting with a 
weakly oncogenic virus, was a precipitating factor for 
tumor development [41]. In separate studies, Walford [43] 
showed an increased incidence of lymphomas in the 
absence of clinical GVHD following transfer of spleno-
cytes across a weak histocompatibility locus into neonatal 
mice. In this model, bilateral immunologic interactions 
were also considered [0 be the likely instigator of the 
tumors. 
Posttransplant Iymphoproliferative disorders 
An increased frequency of lymphoid tumors in transplant 
patients has long been documented. Most tumors arise 
within the first 1 or 2 years following transplantation, and 
they may be single or multiple. The latter may arise from 
individual. unique clones [44J. According to Penn [45], 
approximately 87% of PTLDs arc of B-cell and 13% are 
of T-cell origin. 
The role of EBV in PTLD is well csrablished [46]. III 
z'itro. the latenrly EBV-infected B cell has an "activated" 
phenotype and expresses a number of EBV-Iatency-asso-
ciated proteins [47J. However. [he ill vi'{)o phenotype of 
the latenrlv infected I\,mphocvre mav be that of a restin,!?; 
B cell. with little or no expression of viral antigens [48J. 
The exact ill '{:i'{:o stimulus rhat tirst <Icci\'ares this larenr/v 
infected cell is lInknown. 
The phenotvpe of most EBV·posltivc PTLDs resembles 
that of the activated ill citro EB\'-infected B cell [491. 
The cHokine profile of PTLDs appears to bc a Th.2 
-~--K-K-- ... ~-----------
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pattern (interleukin-4- and interleukin-10-positive) [SOl, 
and this pattern may be reflected systemically by elevated 
serum interleukin-4 and IgE levels, as shown in some 
cases [51]. Remission can often be induced by restoring 
host immunologic controls. using such means as with-
drawal of immunosuppression [2] or administration of 
EBV-specific effector cells [3-5]. This antitumor activity 
often occurs in parallel with mild to severe allograft rejec-
tion. However. in some cases significant rejection does 
not occur and it is possible to maintain the patient on 
minimal or no immunosuppression following tumor reso-
lution. 
The nature of EBV-negative PTLDs has not been as well 
characterized. These tumors tend to arise later than EBV-
positive PTLD and they often resemble non-Hodgkin's 
lymphomas. B- and T-cell forms have been described. 
Some tumors have also been found to be negative for the 
Kaposi sarcoma virus (human herpesvirus 8) (M. A. N .. 
unpublished observations). We have observed occasional 
remission of these rumors, but the prognosis is generally 
considered to be less favorable than that of EBV-positive 
tumors. 
Insights from animal models 
Simple transfer of immune cells with establishment of 
long-term chimerism is associated with an increased rate 
of lymphoma development in small-animal models. This 
risk is related neither to EBV (which does not infect 
rodent cells) nor to iatrogenic immunosuppression. It may 
occur in the presence or absence of GVHD. The same 
type of immune cell transfer may also lead to tolerance, 
but the two phenomena appear to be either partially or 
whollv independent in the experimental setting. 
How might this situation relate to the clinical setting? 
One practical example of immune cell transfer to generate 
tolerance lies in the use of allogeneic blood transfusions 
to enhance the survival of subsequent allografts. The 
mechanism and full extent of the effect of this maneuver 
are still debated [52-57], but there is evidence that the 
leukocyte component mediates changes that lead to 
enhanced graft acceptance [581. At this time there is no 
evidence that blood transfusions predispose to subse-
quent lymphoid tumor. Nevertheless. in one recent study 
[561. four cases of PTLD occurred in 55 recipients who 
received pre crans plant infusion of HLA-DR-mismatched 
blood. This represented a statistically signiticant differ-
ence from the group of 45 patients with DR-matched 
transfusions. none of whom developed PTLD. 
[ncerpretation of the data is clouded by the Llct that two 
of the four patients "'ith PTLD also received 01-.:T3. 
\\hich is also a risk factor for PTLD. 
This findlllL'; concrasts co the e~lrlier-cited smdy showing 
that good HL:\ matching was a potential risk factor for 
PTLD [111. If the murine swdies art! to S<.!f\"C as a guidt!. 
they indicate that both the donor immunocyte inoculum 
size and the specific donor-host HLA types may disclose 
high- and low-risk subpopulations. This also recalls a 
previously mentioned study concluding that HLA-A2 and 
-DR7 were overrepresented among donors of patients 
who developed PTLD [17-]. 
The animal model suggests that a constant interaction 
between the two immune systems, possibly associated 
with a low-grade proliferation of the relevant cells, may 
set up a substrate for neoplasia. In the human situation, 
we may speculate that the omnipresent EBV becomes 
activated due to B-cell involvement in this process, and 
the virus quickly becomes the central figure as it estab-
lishes an uncontrolled proliferation aided by crippled 
downstream immune controls (ie, depressed anti-EBV 
cytotoxic T-cell activity). This would lead to typical 
PTLD. In other cases, we suggest that chronic stimula-
tion of cells may also provoke neoplastic changes in the 
absence of this virus. These tumors may require a longer 
period to develop, because they would not be driven by 
the manic proliferative forces unleashed by EBV. 
Nevertheless, most would originate from the numerically 
dominant immune system, would be more evenly distrib-
uted among the B- and T-cell subsets, and could possibly 
include tumors of other cells, such as dendritic cells, 
participating in the two-way immune interaction. The 
tumors would preferentially occur at sites of host-donor 
interaction. ie, nodal and extranodal sites, as well as the 
allograft. Because these tumors are related to a chronic 
two-way immune interaction, no clear relationship will be 
found between tumor development and either the level 
of immunosuppression or the degree of donor-specific 
tolerance. Likewise, no consistent relationship with a 
single virus will be found. The tumors would show 
changes characteristic of malignancy, such as oncogene or 
tumor suppressor alterations. but it is unlikely that a 
single consistent abnormality will be uncovered. If the 
tumor cells are studied in detail. they may on occasion be 
found to arise from cells with specificity directed toward 
the companion immune system. 
Conclusions 
At present. the EBV paradigm of PTLD reigns supreme. 
and this concept has led to great strides in both our 
understanding of these tumors and our ability to treat this 
disorder. The success of this model may eclipse the 
contribution of other. unrelated cofactors. \Ve have 
attempted to make the case that nonviral factors that exist 
within the posttransplant patient may also be primarY 
concribmors to the lymphomagenic environment. This 
speculation is presented in order to provoke investIga-
tions to contirm or deny this possibility. We suggest that 
there is a crossroad between the development of toleranct! 
.tnd lvmphomagenesis. and this crossroad is identitied as 
the bilateral immunologil' activity that occurs in the 
microchimt!ric transplant patient. 
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